Breast Cancer Clinical Trial
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States
Eligibility Criteria
Inclusion Criteria:
De novo metastatic (stage IV) disease at initial breast cancer diagnosis during 2015-2019
HR+/HER2- molecular subtype at diagnosis
Initiated 1L systemic therapy with palbociclib + AI or AI alone
Exclusion Criteria:
Patients will be excluded if their metastatic breast cancer diagnosis was first recorded in a death certificate or at the time of autopsy.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10001, United States
How clear is this clinincal trial information?